Business Context and Reporting Period
This Form 8-K was filed by Eton Pharmaceuticals, Inc. on April 8, 2021. The report details a secondary public offering of common stock by a selling stockholder, Harrow Health, Inc., rather than a primary offering by the Company.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the specific securities transaction:
- Shares Offered: 1,320,000 firm shares with an option for up to 198,000 additional shares.
- Offering Price: $7.00 per share.
- Expected Gross Proceeds: Approximately $9.24 million (or $10.63 million if the over-allotment option is fully exercised).
- Proceeds to Company: $0. The filing explicitly states Eton Pharmaceuticals will not receive any proceeds from this sale.
Material Changes
The material event reported is the entry into an underwriting agreement for the sale of shares by Harrow Health, Inc. This transaction represents a change in the ownership structure of the Company's outstanding shares but does not constitute a change in the Company's operational financial position or capital structure, as no new capital is being raised by Eton Pharmaceuticals.
Guidance, Outlook, and Risks
The filing contains no management guidance, operational outlook, or discussion of general business risks. Specific contingencies and terms related to the transaction include:
- Closing Date: Expected on or about April 12, 2021, subject to customary conditions.
- Lock-Up Period: The Selling Stockholder has agreed to a 180-day lock-up period, prohibiting further sales of Common Stock without the Underwriter's consent.
- Indemnification: The Company and Selling Stockholder have agreed to indemnify the Underwriter against certain liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify that the Company receives no proceeds from this transaction, confirming it is a secondary offering by Harrow Health, Inc.
- Confirm the final number of shares sold, including whether the 198,000 share over-allotment option was exercised.
- Review the final prospectus supplement filed with the SEC for complete terms of the underwriting agreement.
- Monitor the 180-day lock-up expiration date for potential future selling pressure from the Selling Stockholder.